ImmuneOnco filed the patent application for the invention of Jurkat-CSR cell line

In the invention the gene-operating cell line integrates a chimeric SIRP alpha receptor (CSR molecule) expressing exogenous SIRP alpha protein and its application, as the cell line does not express CD47. The cell line can be used well for screening specific ...

2018-12-14

ImmuneOnco Announced The second Patent Approval by the China Patent Office

The patent involves a CD47 targeted drug, the IMM01 project that has submitted IND applications. This is another major milestone for the company, which indicates that this kind of structured protein drugs will enjoy exclusive market development rights. ...

2018-10-30

ImmuneOnco Announced Patent Approval in Japan

“The Bi-functional protein simultaneously targeting CD47/VEGF is one of many exciting programs in our preclinical development portfolio," said Dr. Wenzhi Tian, Chairman and Chief Executive Officer of ImmuneOnco. "The anti-angiogenesis activity of the protein...

2018-06-23

2018 Team Building

...

2018-05-23

ImmuneOnco 2018 new spring fellowship successfully held

At the party, Dr. Tian Wenzhi enthusiastically introduced the company employees, introduced the company's development and made great achievements in 2017, then looked forward to the new peak of 2018. The company's achievements cannot do without inves......

2018-01-19